RxDoctor Payments Data

Nayvis Iglesias

Family Medicine · Doral, FLNPI 1003002817

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Kowa Pharmaceuticals America, Inc. accounts for 78.6% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $114, 9.2 times the $12 reported in 2021. That places this record below the midpoint for family medicine clinicians in FL, where the typical reported total is $424.

$145in general payments, 2019–2025

Across 3 payments — averaging $48.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kowa Pharmaceuticals America, Inc.$114
  • Johnson & Johnson$19
  • AbbVie$12
$569,993in research payments, 2019–2025

Across 162 payments — averaging $3518.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$211K
  • GSK$152K
  • Teva Pharmaceuticals USA, Inc.$70K
  • Astellas Pharma Global Development$58K
  • Biohaven Pharmaceuticals, Inc.$46K
  • Paratek Pharmaceuticals, Inc.$17K
  • plus $15K from 1 others

What the payments were for

  • Food & beverage$145100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$145 in reported general payments places this provider in the 25th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida →

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban427$238,191
XareltoRivaroxaban259$140,104
TradjentaLinagliptin116$57,892
EntrestoSacubitril/Valsartan56$36,390
Spiriva RespimatTiotropium Bromide61$30,817
Breztri AerosphereBudesonide/Glycopyr/Formoterol41$25,207
BrilintaTicagrelor58$24,666
FarxigaDapagliflozin Propanediol42$23,919
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate147$22,667
JardianceEmpagliflozin30$17,452
Clobetasol Propionate137$14,501
GemtesaVibegron27$12,564
OzempicSemaglutide13$12,059
Oxybutynin Chloride ErOxybutynin Chloride98$11,065
Benzonatate412$10,891

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$19$140,104259 claims
AbbVieRestasis$12$9,80916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Doral

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →